Clinical trial · Interventional
Skin Protection During Radiotherapy in Patients With Breast Cancer
Skin Protection During Radiotherapy in Patients With Breast Cancer: A Comparative Study of Evoskin® Verus Trixéra®
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiotherapy may cause severe skin changes that significantly interfere with the patient's quality of life and may reduce radiotherapy effectiveness. Many skin care instructions and various topical agents are recommended to help patients in the management of radiation skin reactions, but evidence to support the value of the topical treatments of the irradiated skin is lacking. In the present study we investigated the effects of two topical agents used as supportive care to protect skin during radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiation Dermatitis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Evoskin | Drug | — | UNRESOLVED |
| Trixiera | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- EVOSKIN
- description
- Patients are to apply Evoskin ( topical agent) in the half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
- interventionNames
- Drug: Evoskin
- type
- ACTIVE_COMPARATOR
- label
- TRIXIERA
- description
- Patients are to apply Trixiera ( topical agent) in the other half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
- interventionNames
- Drug: Trixiera
Primary outcomes (1)
- measure
- Average of the radiation dermatitis intensity
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years old or more * Patients with breast cancer for which a treatment by radiotherapy is planned * No concomitant chemotherapy * Signed informed consent Exclusion Criteria: * Cutaneous neoplasia radiotherapy * Total mastectomy * Bilateral breast cancer * Dark skinDiseases enhancing radiosensitivity Patient with a generalized skin disorder * Pregnant, breast-feeding woman
References
Publications (0)
Data not yet available